Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc.

BIOยทNYSE

$304.83

+0.14%
HealthcareMedical - Devices

Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

At a Glance

Live Snapshot
Market Cap$8.24B
EPS27.8700
P/E Ratio10.94
Earnings Date07/30/2026
3Y+174.0%
5Y-9.0%
10Y+146.0%
3Y-84.0%
5Y+171.0%
10Y-11.0%
3Y-129.0%
5Y-46.0%
10Y-3240.0%
BIO

Bio-Rad Laboratories, Inc. Cash Conversion Engine

BIO ยท NYSE
Net Income759.90M
Depreciation & Amortization205.40M
Stock-Based Compensation0.00
Change in Working Capital275.60M
Others-879.20M
Capital Expenditures-157.60M
Free Cash Flow374.60M

Cash Flow Quality Analysis

FCF Conversion Rate

49.3%

Weak cash conversion. Significant portion of earnings not converting to cashโ€”review working capital trends and capital intensity.

CapEx Intensity

29.6%

Moderate capital requirements typical of many stable businesses. Healthy balance between reinvestment and cash generation.

FCF Growth Trend

+40.7%

Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.

Working Capital Impact

+$275.60M

Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.

Bio-Rad Laboratories, Inc. Cash Flow Statement

BIO โ€ข NYSE

Bio-Rad Laboratories, Inc. Cash Flow StatementDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015Dec 2014Dec 2013Dec 2012Dec 2011Dec 2010Dec 2009Dec 2008Dec 2007Dec 2006
OPERATING ACTIVITIES
759.9M
-1.8B
-637.3M
-3.6B
4.3B
3.8B
1.8B
365.6M
122.2M
26M
109.2M
88.8M
77.8M
165.5M
178.8M
186.9M
149.2M
98.3M
93M
103.3M
205.4M
151.6M
145.9M
137.3M
137.6M
138.6M
134.2M
138.1M
148.7M
142.9M
131.8M
149.9M
147.2M
130.4M
121M
108.9M
101.7M
97.1M
67.3M
55.4M
170.5M
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
-5.9M
1.2M
0.0
62.3M
61.3M
60.9M
51.2M
41.6M
35.6M
27.8M
23.4M
19.7M
17M
14.9M
13.7M
13.2M
10.7M
10.2M
9.1M
7.3M
0.0
5.4M
-879.2M
2.7B
1.2B
5.2B
-4.9B
-4.5B
-2B
-323M
13.5M
66.6M
-5.6M
2M
-7.4M
-30.4M
-1.5M
-1.2M
10M
38.5M
26.1M
-36.7M
275.6M
-620.8M
-432.8M
-1.6B
1.1B
1.1B
555.9M
77M
-203.7M
-39.1M
-66.2M
17.7M
-62.2M
-12.2M
-46.3M
-78.9M
55.1M
-49.8M
11.1M
-10.3M
532.2M
455.2M
374.9M
194.4M
669.5M
585M
457.9M
285.5M
104.1M
216.1M
186.2M
273.3M
169.1M
266.5M
262.7M
225.9M
325.1M
191.4M
191.6M
118.2M
INVESTING ACTIVITIES
-157.6M
-165.6M
-156.7M
-112.8M
-133.7M
-108.6M
-98.5M
-129.8M
-115.1M
-141.6M
-113.4M
-136.5M
-107.4M
-144.6M
-103.3M
-92.5M
-76.4M
-88.8M
-62.7M
-53M
-218.4M
(0.0)
(2.5M)
-99.4M
-125.5M
-84.4M
-79.4M
(7M)
(0.0)
(0.0)
-4.4M
-44.6M
-72.1M
-39.4M
-158.5M
-89.3M
-36M
-53M
-387.7M
-46.1M
-669.3M
-1.3B
-689M
-2.1B
-851.6M
-248.5M
-371.5M
-371M
-359.3M
-292.2M
-294.5M
-205.7M
-386.7M
-681M
-509.3M
-240.3M
-147.6M
-77.8M
-270.2M
-334M
62M
1.3B
863.2M
1.1B
766.9M
368.1M
331.5M
302.6M
299.8M
219.9M
249.5M
196.1M
565.8M
458.3M
384.6M
210.8M
86.5M
78.9M
470.2M
178.6M
793.6M
-23.3M
211K
-1.2M
-453.4M
3.5M
8.9M
4.3M
-914K
48K
-4.1M
225K
1.2M
6.3M
234K
-5.2M
-2.5M
-5.4M
-4.1M
46.7M
-189.7M
-160.2M
(20.2M)
-1.2B
-797.4M
-69.9M
-208.9M
-187M
-175.6M
-213.9M
-166.9M
-190.5M
(919K)
-400.4M
-386.3M
-216.5M
-176M
-146.1M
-254.4M
-207.7M
FINANCING ACTIVITIES
-279.7M
-203.6M
-428.7M
-215.7M
-50M
-100M
-28M
-48.9M
-2.9M
0.0
8.2M
15.1M
11.2M
10.5M
14.2M
12.7M
10.3M
12.9M
11.6M
9.9M
-500K
-400K
-467K
1.2B
-3M
-426.9M
-643K
-3M
-352K
-266K
-282K
-1.8M
-300.2M
-811K
-230.7M
217.1M
285.6M
-11.6M
-22M
-1.1M
-295.5M
-203.6M
-428.7M
-215.7M
-50M
-100M
-28M
-48.9M
-2.9M
(0.0)
(0.0)
(0.0)
(0.0)
-101K
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
(0.0)
-3M
-14.8M
3.5M
3.5M
-2.4M
3.9M
5.9M
3.2M
3.6M
9.3M
627K
-1.5M
-22.8M
2.9M
2.9M
-1.1M
-2M
5.1M
3M
1.4M
-283.2M
-218.8M
-425.6M
973.6M
-55.4M
-523M
-22.8M
-48.7M
341K
9M
8.6M
11.7M
-311.7M
12.6M
-213.6M
228.7M
293.9M
6.3M
-7.5M
10.2M
CASH FLOW SUMMARY
-19M
9.2M
321K
3M
-12.6M
12.4M
2.2M
-655K
-1.1M
-12.9M
16.4M
-12.8M
9.8M
10.5M
4.8M
18.5M
2.4M
-8.8M
8.5M
6.2M
40.3M
85.4M
-30.2M
-36.6M
-196M
4.5M
228.5M
49.2M
-72.2M
-1.7M
44.3M
81.7M
-131.8M
-110.8M
-332.3M
256.6M
445.4M
42.8M
-61.8M
-73.1M
489.8M
404.4M
434.5M
471.1M
667.1M
662.7M
434.2M
385M
457.2M
458.8M
413.3M
331.6M
463.4M
574.2M
906.6M
649.9M
204.5M
161.8M
223.6M
296.7M
532.2M
489.8M
404.4M
434.5M
471.1M
667.1M
662.7M
434.2M
385M
457.2M
457.5M
413.3M
331.6M
463.4M
574.2M
906.6M
649.9M
204.5M
161.8M
223.6M
374.6M
266.2M
218.3M
80.3M
535.7M
476.4M
359.4M
155.7M
-11M
74.5M
72.8M
136.8M
61.8M
121.8M
159.4M
133.4M
248.7M
102.6M
128.9M
65.2M

SEC Filings

BIO - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
8-K

8-K 2026

N/A

April 30, 2026
April 30, 2026
2026
10-Q

10-Q 2026 Q1

Q1

April 30, 2026
March 31, 2026
2026
8-K

8-K 2026

N/A

April 24, 2026
April 21, 2026
2026
DEF 14A

DEF 14A 2026

N/A

March 25, 2026
April 21, 2026
2026
8-K

8-K 2026

N/A

February 19, 2026
February 19, 2026
2026
10-K

10-K 2025 FY

FY

February 13, 2026
December 31, 2025
2025
8-K

8-K 2026

N/A

February 12, 2026
February 12, 2026
2026
8-K

8-K 2025

N/A

October 29, 2025
October 29, 2025
2025
10-Q

10-Q 2025 Q3

Q3

October 29, 2025
September 30, 2025
2025
8-K

8-K 2025

N/A

September 30, 2025
September 29, 2025
2025
Showing 1 to 10 of 369 filings